Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder.
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder.
复制标题
DOI：
10.1097/jcp.0b013e31823f3b5f
复制
发表时间：
2012-02
影响因子：
2.9
通讯作者：
Rapaport MH
中科院分区：
文献类型：
--
作者：
Gertsik L;Poland RE;Bresee C;Rapaport MH
本研究的目的是探讨西酞普兰加 omega-3 脂肪酸联合治疗与西酞普兰加安慰剂（橄榄油）在重度抑郁症 (MDD) 患者初始治疗中的疗效。我们假设联合治疗不仅会产生更大的疗效，而且会更快地产生治疗反应。 42 名受试者参加了这项为期 9 周的随机、隐蔽、安慰剂对照研究，比较 MDD 的联合疗法（2 克，含有 900 毫克 EPA、200 毫克 DHA 和 100 毫克其他 omega-3 脂肪酸的混合物，每天两次，加上西酞普兰）与单一疗法（每天 2 克橄榄油，加上西酞普兰）治疗 MDD。从第 4 周开始（t = -2.48，df 38，p = 0.018），联合治疗显示汉密尔顿抑郁量表评分显着改善，并持续到研究的其余部分（F = 7.32，df 1,177，p = 0.008）。在 8 周的积极治疗期间，联合治疗比单一疗法在减少 MDD 体征和症状方面更有效，但联合治疗似乎并没有提高初始抗抑郁反应的速度。这些研究结果表明，在 MDD 患者的初始治疗中，将 omega-3 脂肪酸与选择性血清素摄取抑制剂相结合可能具有优势。有必要进行更大规模的明确研究。
The objective of this study was to explore the efficacy of combination therapy with citalopram plus omega-3 fatty acids versus citalopram plus placebo (olive oil) in the initial treatment of individuals with Major Depressive Disorder (MDD). We hypothesized that combination therapy would not only lead to greater efficacy, but a more rapid onset of therapeutic response. Forty-two subjects participated in this nine week randomized, masked, placebo-controlled study of combination therapy (2 grams containing a blend of 900mg EPA, 200mg DHA, and 100mg other omega-3 fatty acids twice daily plus citalopram) versus monotherapy (2 grams olive oil per day plus citalopram) treatment of MDD. The combination therapy demonstrated significantly greater improvement in Hamilton Depression Rating scales scores beginning at week 4 (t = −2.48, df 38, p = 0.018) and continuing throughout the rest of the study (F = 7.32, df 1,177, p = 0.008). Combination therapy was more effective than monotherapy in decreasing signs and symptoms of MDD during the 8 weeks of active treatment, however, combination therapy did not seem to enhance the speed of the initial antidepressant response. These findings suggest that there may be an advantage to combining omega-3 fatty acids with a selective serotonin uptake inhibitor in the initial treatment of individuals with MDD. A larger definitive study is warranted.